Operationalizing TAR-200 and Other Delivery Systems in Practice

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.Cystectomy in NMIBC

EP: 3.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 4.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 5.TAR-200 Clinical Development Program in NMIBC

EP: 6.Other Investigational Drug Delivery Systems in NMIBC

EP: 7.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 8.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 9.Use and Sequencing of Novel Treatments in NMIBC

EP: 10.Communication of Treatment Options for High-Risk NMIBC

EP: 11.Checkpoint Inhibitors for Treatment of NMIBC

EP: 12.Unmet Needs in NMIBC

Now Viewing

EP: 13.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 14.Patient Communication and Treatment Adherence in NMIBC

EP: 15.Uptake of New Treatments in Urology Practice

EP: 16.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices?
What challenges do you anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices?